(Q46854681)

English

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

scientific article published on 16 January 2017

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/28110911

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/28110911

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

semaglutide

5 May 2024

author name string

Christopher Sorli

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/28110911

Shin-Ichi Harashima

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/28110911

George M Tsoukas

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/28110911

Jeffrey Unger

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/28110911

Julie Derving Karsbøl

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/28110911

Thomas Hansen

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/28110911

Stephen C Bain

7

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/28110911

publication date

16 January 2017

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/28110911

The Lancet: Diabetes & Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/28110911

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/28110911

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/28110911

251-260

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/28110911

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-cont

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient perspectives on once-weekly medications for diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A Plethora of GLP-1 Agonists: Decisions About What to Use and When

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Ph

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Obesity as a disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life in relation to overweight and body fat distribution.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Measuring beliefs about taking hypoglycaemic medication among people with Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930013-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-8587(17)30013-X

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/28110911

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/28110911

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46854681&oldid=2145722246"